Skip to content
ApprovedFDA approvedModerate evidence

Opipramol

Prescription anti-anxiety medicine for generalized anxiety and stress-related physical complaints, approved in Europe.

AnxiolyticAtypical tricyclicAnxiolyticMoodnoo.affects.sigmanoo.affects.histamineSerotonin

Pharmacology

ClassAnxiolytic · Mood
Primary targetSigma receptor ligand + H1 antagonist
Targets3 receptor targets
Half-lifeAbout 6-11 hours (suitable for once-daily evening dosing)
OnsetSedation appears within hours; the full anxiolytic effect builds over 1-3 weeks
EvidenceModerate evidence
Affected systemsnoo.affects.sigmanoo.affects.histamineSerotonin

Contents

DETAILED OVERVIEW

What is Opipramol?

Opipramol is a prescription medicine approved in several European countries, for example Germany and Poland, for generalized anxiety and for disorders that show up as physical symptoms (somatoform disorders). It is not approved in the United States and is not sold there.

Its structure resembles the older antidepressants, but it does not work like them: it binds to proteins that regulate the nerve cells' stress response and blocks one of the histamine receptors, which calms and makes drowsy. In a placebo-controlled trial its anti-anxiety effect was similar to that of alprazolam, without the dependence and loss of effect typical of benzodiazepine-type sedatives. It can cause tiredness, dry mouth, dizziness on standing up and weight gain; liver function and blood count changes are rare, so periodic checks are recommended. It must not be given together with MAO inhibitors or in acute alcohol or sleeping-pill poisoning. In pregnancy and breastfeeding it is used only when there is a clear medical reason.

Mechanism

Sigma-1/2 ligand + H1 antagonist

Half-life

About 11 hours (once-daily dosing)

Legal status

Prescription medicine (EU), not in US

Receptor profile

  • Sigma-1 / sigma-2 receptorsStrong
  • Histamine H1 receptorStrong
  • D2 / 5-HT2 receptors (weak)Weak

Safety

Side effects, stop signs, contraindications

Side effects · 5

  • Tiredness and drowsiness, especially in the first days of treatment (H1 blockade)
  • Dry mouth and other mild anticholinergic-type effects
  • Orthostatic hypotension: dizziness or lightheadedness on standing
  • Weight gain and increased appetite with longer use
  • Rare liver function and blood count changes, so periodic monitoring is advised

Contraindications · 5

  • Acute intoxication with alcohol, hypnotics, analgesics or psychotropic drugs
  • Urinary retention, narrow-angle glaucoma, severe prostate enlargement (anticholinergic effect)
  • Should not be combined with MAO inhibitors or given immediately after stopping them
  • Severe liver or kidney impairment and known QT prolongation require increased caution
  • Pregnancy and breastfeeding: only under a clear medical indication after risk-benefit assessment

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

Opipramol is a prescription medicine used mainly to treat generalized anxiety, with effects comparable to classic anti-anxiety medications, but without the usual dependence or tolerance buildup associated with them. It is also used for stress-related complaints that show up as physical symptoms, and it has a mild calming, sleep-supporting effect, so a single evening dose is often enough. Because it works through a different mechanism than typical anxiety medications, its overall profile is distinct from benzodiazepines.

Telegram

Have a question about Opipramol?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeAnxiolytic
FormulaC23H29N3O
UpdatedOctober 13, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.